Genprex diabetes gene therapy GPX-002 reverses hyperglycemia in T2D mouse model

Genprex, Inc.

Preclinical data presented at ASGCT 2026 showed GPX-002 reversed hyperglycemia in Type 2 diabetic mice within 4 weeks.
Treatment improved β-cell function: increased insulin granules, improved glucose-stimulated insulin secretion vs controls.
β-cell-specific targeting (RIP-PM-GFP) also reversed hyperglycemia, indicating enhanced β-cell maturation.
Approach is translatable to humans via endoscopic retrograde cholangiopancreatography delivery to the pancreas.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.